{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:16:04Z","timestamp":1760188564050},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2005,8,1]],"date-time":"2005-08-01T00:00:00Z","timestamp":1122854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2005,8,1]],"date-time":"2005-08-01T00:00:00Z","timestamp":1122854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2005,10,1]]},"DOI":"10.1038\/sj.bmt.1705112","type":"journal-article","created":{"date-parts":[[2005,8,2]],"date-time":"2005-08-02T05:43:57Z","timestamp":1122961437000},"page":"591-596","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Autologous transplantation for primary systemic AL amyloidosis is feasible outside a major amyloidosis referral centre: the Calgary BMT Program experience"],"prefix":"10.1038","volume":"36","author":[{"given":"L Q M","family":"Chow","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Bahlis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Russell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Chaudhry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Morris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D A","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2005,8,1]]},"reference":[{"key":"BF1705112_CR1","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/00005792-197507000-00001","volume":"54","author":"RA Kyle","year":"1975","unstructured":"Kyle RA, Bayrd ED . Amyloidosis: review of 236 cases. Medicine (Baltimore) 1975; 54: 271\u2013299.","journal-title":"Medicine (Baltimore)"},{"key":"BF1705112_CR2","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1093\/qjmed\/91.2.141","volume":"91","author":"SW Dubrey","year":"1998","unstructured":"Dubrey SW, Cha K, Anderson J et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM 1998; 91: 141\u2013157.","journal-title":"QJM"},{"key":"BF1705112_CR3","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/0002-9343(85)90521-2","volume":"79","author":"RA Kyle","year":"1985","unstructured":"Kyle RA, Greipp PR, Garton JP et al. Primary systemic amyloidosis: comparison of melphalan\/prednisone vs colchicine. Am J Med 1985; 79: 708\u2013716.","journal-title":"Am J Med"},{"key":"BF1705112_CR4","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/S0002-9343(97)89487-9","volume":"100","author":"M Skinner","year":"1996","unstructured":"Skinner M, Anderson J, Simms R et al. Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone and colchicine vs colchicine only. Am J Med 1996; 100: 290\u2013298.","journal-title":"Am J Med"},{"key":"BF1705112_CR5","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1056\/NEJM199704243361702","volume":"336","author":"RA Kyle","year":"1997","unstructured":"Kyle RA, Gertz MA, Greipp PR et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone and colchicine. N Engl J Med 1997; 336: 1202\u20131207.","journal-title":"N Engl J Med"},{"key":"BF1705112_CR6","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1182\/blood.V91.10.3662","volume":"91","author":"RL Comenzo","year":"1998","unstructured":"Comenzo RL, Vosburgh E, Falk RH et al. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light chain) amyloidosis: survival and response in 25 patients. Blood 1998; 91: 3662\u20133670.","journal-title":"Blood"},{"key":"BF1705112_CR7","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1046\/j.1365-2141.1998.00772.x","volume":"101","author":"P Moreau","year":"1998","unstructured":"Moreau P, Leblond V, Bourquelot P et al. Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in system AL amyloidosis: a report on 21 patients. Br J Hematol 1998; 101: 766\u2013769.","journal-title":"Br J Hematol"},{"key":"BF1705112_CR8","first-page":"324a","volume":"82","author":"MA Gertz","year":"1998","unstructured":"Gertz MA, Lacy MQ, Dispenzieri A . Treating AL amyloidosis (AL) with dose-intensive melphalan: outcomes in 102 patients. Blood 1998; 82: 324a.","journal-title":"Blood"},{"key":"BF1705112_CR9","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/sj.bmt.1702178","volume":"25","author":"MA Gertz","year":"2000","unstructured":"Gertz MA, Lacy MQ, Dispenzieri A . Myeloablative chemotherapy with stem cell rescue for the treatment of primary systemic amyloidosis: a status report. Bone Marrow Transplant 2000; 25: 465\u2013470.","journal-title":"Bone Marrow Transplant"},{"key":"BF1705112_CR10","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/sj.bmt.1703200","volume":"28","author":"V Sanchorawala","year":"2001","unstructured":"Sanchorawala V, Wright DG, Seldin DC et al. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplant 2001; 28: 637\u2013642.","journal-title":"Bone Marrow Transplant"},{"key":"BF1705112_CR11","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1038\/sj.bmt.1702005","volume":"24","author":"N Saba","year":"1999","unstructured":"Saba N, Sutton DM, Ross JH et al. High treatment-related mortality in cardiac amyloid patients undergoing autologous stem cell transplant. Bone Marrow Transplant 1999; 24: 853\u2013855.","journal-title":"Bone Marrow Transplant"},{"key":"BF1705112_CR12","doi-asserted-by":"publisher","first-page":"3960","DOI":"10.1182\/blood-2003-12-4192","volume":"103","author":"A Dispenzieri","year":"2004","unstructured":"Dispenzieri A, Kyle RA, Lacy MQ et al. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case\u2013control study. Blood 2004; 103: 3960\u20133963.","journal-title":"Blood"},{"key":"BF1705112_CR13","first-page":"3350","volume":"2001","author":"A Disperzieri","year":"1919","unstructured":"Disperzieri A, Lacy MQ, Kyle RA et al. Eligibility for hematopoietic stem cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. J Clin Oncol 19; 2001: 3350\u20133356.","journal-title":"J Clin Oncol"},{"key":"BF1705112_CR14","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/sj.bmt.1704344","volume":"33","author":"P Mollee","year":"2004","unstructured":"Mollee P, Wechalekar AD, Peireira D . Autologous stem cell transplantation in primary systemic amyloidosis: the impact of selection criteria on outcome. Bone Marrow Transplant 2004; 33: 271\u2013277.","journal-title":"Bone Marrow Transplant"},{"key":"BF1705112_CR15","doi-asserted-by":"publisher","first-page":"4276","DOI":"10.1182\/blood.V99.12.4276","volume":"99","author":"RL Comenzo","year":"2002","unstructured":"Comenzo RL, Gertz MA . Autologous stem cell transplantation for primary systemic amyloidosis. Blood 2002; 99: 4276\u20134282.","journal-title":"Blood"},{"key":"BF1705112_CR16","doi-asserted-by":"publisher","first-page":"85","DOI":"10.7326\/0003-4819-140-2-200401200-00008","volume":"140","author":"M Skinner","year":"2004","unstructured":"Skinner M, Sanchorawala V, Seldin DC et al. High dose melphalan and autologous stem cell transplantation in patients with AL amyloidosis: an 8 year study. Ann Intern Med 2004; 140: 85\u201393.","journal-title":"Ann Intern Med"},{"key":"BF1705112_CR17","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/sj.bmt.1704539","volume":"34","author":"MA Gertz","year":"2004","unstructured":"Gertz MA, Blood E, Vesole DH et al. A multicenter phase 2 trial of stem cell transplantation for immunoglobulin light-chain amyloidosis (E4A97): an Eastern Cooperative Oncology Group Study. Bone Marrow Transplant 2004; 34: 149\u2013154.","journal-title":"Bone Marrow Transplant"},{"key":"BF1705112_CR18","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1056\/NEJMoa013354","volume":"346","author":"HJ Lachmann","year":"2002","unstructured":"Lachmann HJ, Booth DR, Booth SE et al. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med 2002; 346: 1786\u20131791.","journal-title":"N Engl J Med"},{"key":"BF1705112_CR19","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1182\/blood-2004-01-0390","volume":"104","author":"A Dispenzieri","year":"2004","unstructured":"Dispenzieri A, Gertz MA, Klye RA et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2004; 104: 1881\u20131887.","journal-title":"Blood"},{"key":"BF1705112_CR20","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/sj.bmt.1704346","volume":"33","author":"V Sanchorawala","year":"2004","unstructured":"Sanchorawala V, Wright DG, Seldin DC et al. High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial. Bone Marrow Transplant 2004; 33: 381\u2013388.","journal-title":"Bone Marrow Transplant"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/1705112","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1705112.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1705112.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T00:19:53Z","timestamp":1648081193000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/1705112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8,1]]},"references-count":20,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2005,10,1]]}},"alternative-id":["BF1705112"],"URL":"https:\/\/doi.org\/10.1038\/sj.bmt.1705112","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,8,1]]},"assertion":[{"value":"1 October 2004","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2005","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2005","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}